Intro

u88_start u88_end u88_line

Healing

Process

u91_start u91_end u91_line
u92_start u92_end u92_line

 

Find a

Physician

Treatment

Comparison

u107_start u107_end u107_line

Safety

Information

BIAFINE Topical Emulsion promotes healing in damaged skin

BIAFINE is a topical, water-based emulsion that helps damaged skin heal and helps manage wounds, burns, and other skin abrasions 1 . It is used for the dressing and management of:

  • Wounds
  • Pressure sores
  • Leg ulcers
  • 1st and 2nd degree burns including sunburns
  • Donor and graft sites
  • Skin reactions to radiation therapy
  • Minor scrapes

BIAFINE should not be used on any wound until directed by a healthcare professional. Do not use BIAFINE on bleeding wounds, skin rashes related to food or medicine allergies, or when an allergy to one of the ingredients is known.

Click here for full Instructions for Use.

Proven BIAFINE Formulation Impacts All Phases of the
Healing Process

Provides an effective barrier

BIAFINE provides an optimum moist environment for the healing process and isolates the wound from harmful germs and other external contamination. 1

Impacts the healing process

BIAFINE impacts the healing process by increasing macrophage levels. 2,3 Macrophages are immune cells which aid the healing process during all 3 phases of the healing process:

  • Inflammation
  • Proliferation
  • Maturation

Comparison of Treatment

* This patient is representative of the results observed 4 .
Photos are unretouched. Results may vary.

Split face study: comparison of treatment after laser resurfacing (N=30)* 4

BIAFINE promoted skin healing in aesthetic surgery and laser resurfacing patients.

For postprocedure treatment of the whole face, BIAFINE was applied to one side and petrolatum to the other side twice daily for 3 days, then once daily through day 8.

Talk to your skin care physician to see if
BIAFINE is right for you.

Don’t have a physician? Find a physician at Obagi.com.


Indications

BIAFINE Topical Emulsion is used for the dressing and management of wounds, pressure sores, leg ulcers, 1st and 2nd degree burns including sunburns, donor and graft sites, skin reactions to radiation therapy, and minor scrapes.

Important Safety Information

BIAFINE should not be used on any wound until directed by a healthcare professional. Do not use BIAFINE on bleeding wounds, skin rashes related to food or medication allergies, or when an allergy to one of the ingredients is known.

Do not apply BIAFINE within 4 hours of a radiation session and do not miss an application during the course of radiation therapy, even for one day.

Do not apply BIAFINE to a skin graft until your healthcare professional has instructed you to do so.

BIAFINE is for topical use only. If swallowed, contact a healthcare professional or Poison Control Center immediately. Keep out of reach of children.

BIAFINE should not be used prior to extended exposure to the sun. Following application of BIAFINE a temporary tingling sensation may occur (10 to 15 minutes).

If a wound has become infected, your healthcare professional will advise you whether to continue the use of BIAFINE while being treated with an anti-infective.

If your condition doesn’t improve within 10-14 days, see your healthcare professional.

See Instructions for Use for detailed directions for the proper use of BIAFINE on various types of wounds and burns. See your healthcare professional if you have any questions or concerns.


Not available in select states including MA, MT, NH, NY, and TX, due to state regulations regarding the ability of physicians to dispense prescription drug products in their offices.


References: 1. BIAFINE topical emulsion [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals; 2012. 2. Coulomb B, Friteau L, Dubertret L. Biafine applied on human epidermal wounds is chemotactic for macrophages and increases the IL-1/IL-6 ratio. Skin Pharmacol. 1997;10(5-6):281-287. 3. Boisnic S, Branchet-Gumila M-C, Nizri D, Ben Slama L. Histochemical and biochemical modifications induced by experimental irradiation of human skin maintained in survival conditions and modulation by application of an emulsion containing trolamine. Int J Tissue React. 2003;25(1):9-18. 4. Dr. Rendon Investigator Initiated Study. June 25, 2007. Data on file. Valeant Pharmaceuticals.